References
- Roberts RL , KennedyMA. Rapid detection of common cytochrome P450 2D6 alleles in Caucasians. Clin. Chim. Acta366(1–2) , 348–351 (2006).
- Taylor DR , EptonMJ, KennedyMA et al. Bronchodilator response in relation to {β}2-adrenoceptor haplotype in patients with asthma. Am. J. Respir. Crit. Care Med. 172(6) , 700–703 (2005).
- Jensen BP , SharpCF, GardinerSJ, BeggEJ. Development and validation of a stereoselective liquid chromatography-tandem mass spectrometry assay for quantification of S- and R-metoprolol in human plasma. J. Chromatography B. Anal. Technol. Biomed. Life Sci.865(1–2) , 48–54 (2008).
- Zhang M , MooreGA, BarclayML, BeggEJ. Determination of perhexiline and its metabolite hydroxyperhexiline in human plasma by liquid chromatography/tandem mass spectrometry. J. Chromatogr. B. Anal. Technol. Biomed. Life Sci.877(27) , 3025–3030 (2009).
- Jensen BP , ChinPK, BeggEJ. Quantification of total and free concentrations of R- and S-warfarin in human plasma by ultrafiltration and LC-MS/MS. Anal. Bioanal. Chem.401(7) , 2187–2193 (2011).
- Roberts RL , LutySE, MulderRT, JoycePR, KennedyMA. Association between cytochrome P450 2D6 genotype and harm avoidance. Am. J. Med. Genet. Part B Neuropsych. Genet.127B(1) , 90–93 (2004).
- Roberts RL , GearryRB, BlandMV et al. Trinucleotide repeat variants in the promoter of the thiopurine S-methyltransferase gene of patients exhibiting ultra-high enzyme activity. Pharmacogenet. Genomics 18(5) , 434–438 (2008).
- Roberts RL , GearryRB, BarclayML, KennedyMA. IMPDH1 promoter mutations in a patient exhibiting azathioprine resistance. Pharmacogenomics J.7(5) , 312–317 (2007).
- Stamp LK , ChapmanPT, O‘DonnellJL et al. Polymorphisms within the folate pathway predict folate concentrations but are not associated with disease activity in rheumatoid arthritis patients on methotrexate. Pharmacogenet. Genomics 20(6) , 367–376 (2010).
- Stamp LK , RobertsRL. Effect of genetic polymorphisms in the folate pathway on methotrexate therapy in rheumatic diseases. Pharmacogenomics12(10) , 1449–1463 (2011).
- McHugh PC , JoycePR, DengX, KennedyMA. A polymorphism of the GTP-cyclohydrolase I feedback regulator gene alters transcriptional activity and may affect response to SSRI antidepressants. Pharmacogenomics J.11(3) , 207–213 (2011).
- Glubb DM , McHughPC, DengX, JoycePR, KennedyMA. Association of a functional polymorphism in the adrenomedullin gene (ADM) with response to paroxetine. Pharmacogenomics J.10(2) , 126–133 (2010).
- McHugh PC , JoycePR, KennedyMA. Polymorphisms of sepiapterin reductase gene alter promoter activity and may influence risk of bipolar disorder. Pharmacogenet. Genomics19(5) , 330–337 (2009).
- McHugh P , RogersG, GlubbD, JoyceP, KennedyM. Proteomic analysis of rat hippocampus exposed to the antidepressant paroxetine. J. Psychopharmacol.24(8) , 1243–1251 (2009).
- Gardiner SJ , BeggEJ. Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol. Rev.58(3) , 521–590 (2006).
- Begg EJ , HelsbyNA, JensenBP. Pharmacogenetics of drug-metabolizing enzymes: the prodrug hypothesis. Pharmacogenomics13(1) , 83–89 (2012).
▪ Websites
- The Carney Centre for Pharmacogenomics. www.pgx.org.nz
- Jim and Mary Carney Charitable Trust. www.otago.ac.nz/christchurch/research/carneycentre/otago028783.html
- Leading Thinkers: what has been achieved? www.alumni.otago.ac.nz/page.aspx?pid=478
- New Zealand Genomics Ltd. www.nzgenomics.co.nz
- Annual Carney Pharmacogenomics Symposia. www.otago.ac.nz/christchurch/research/carneycentre/symposium
- ASCEPT. www.ascept.org